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The objective of this study was to evaluate the 
feasibility, reliability, validity and responsiveness of 
the HIV Overview of Problems Evaluation System 
(HOPES) in a Dutch sample. The HOPES was 
administered three times in a one-year period to a 
sample of 106 outpatients with a symptomatic HIV- 
infection (n = 23) or AIDS (n = 83). The HOPES is a 
self-report HIV-specific quality of life (QOL) 
questionnaire including five scales: physical, psycho- 
social and sexual functioning, medical interaction 
and partner relationship. QOL was also assessed 
with the EORTC Quality of Life Questionnaire 
(EORTC QLQ-CXO), a 30-item self-report instrument. 
Clinical data included Centers for Disease Control 
and Prevention (CDC) stage, date of diagnosis and 
CD4 cell count. Patients needed approximately 20- 
30 minutes to complete the questionnaire. The five 
scales had good internal consistency reliability. 
Multitrait scaling analysis provided moderate sup 
port for item discrlminant and convergent validity. 
The HOPES exhibited adequate levels of construct 
validity: (1) the inter-scale correlations and corre- 
lations with the EORTC QLQ-C30 were in the predicted 
direction; (2) it discriminated clearly between 
patients with AIDS and ARC and (3) it was able to 
document changes in QOL over time. Moreover, the 
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HOPES was responsive to changes in clinical status 
over time as indicated by CD4 counts. This study 
provides further evidence of the reliability and 
validity of the HOPES and shows that this instrument 
is responsive to changes in CD4 cell counts. 
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Introduction 
AIDS or a symptomatic HIV infection can have 
devastating effects on patients’ quality of life (QOL). 
In the short-run, patients are confronted with the 
physical and (possibly) neurological deficits associ- 
ated with the disease, but they also have to accept 
the resulting discontinuation of work, limitations in 
social activities and the increased dependence on 
significant others (e.g., partners, relatives or friends). 
To provide appropriate medical and psychosocial care 
to HIV-infected patients, the immediate and long- 
term effects of the disease and treatment on patients’ 
QOL need to be thoroughly understood. Toward this 
end, reliable and valid instruments are required that 
are also responsive to clinical changes in health status 
over time. 
In 1989, when the current study was initiated, psycho- 
metrically robust measures that were specifically 
designed to assess the QOL and needs of HIV-infected 
patients were scarce. To our knowledge, the only 
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instrument then available was the HIV Overview of 
Problems Evaluation System (HOPES). The HOPES is 
derived from the Cancer Rehabilitation System (CARES), 
a 136item self-administered, cancer-specific instru- 
ment that has been studied extensively in a range of 
cancer patient populations. The HOPES covers a wide 
range of daily problems HIV-infected patients may 
experience, including sexual problems, and problems 
with a partner and the medical team. In a recent study 
among 316 HIV-infected patients, the HOPES demon- 
strated adequate internal consistency reliability.‘,’ 
Further, concurrent validity was demonstrated with 
reference to the following criteria: the Medical 
Outcomes Study questionnaire adapted for HIV 
(MOS-HIV),3,4 the Profile of Mood States (POMS), 
the Perceived Adjustment to Chronic Illness Scale 
(PACIS)6 and the Physical Activity Scale (PAS).’ 
The current study was undertaken to investigate 
the feasibility of employing the HOPES among 
patients treated in the Netherlands, to provide further 
evidence of the instrument’s validity and reliability 
and to examine its responsiveness to changes in clinical 
status over time. 
Methods 
Subjects 
One hundred and six patients were recruited from 
two patient groups: 45 patients were enrolled in a 
randomized clinical trial comparing the efficacy and 
tolerance of zidovudine monotherapy vs. a combination 
of zidovudine and interferon-or; the remaining 61 
subjects were outpatients (not treated in a trial 
context) attending one of the five hospitals in Am- 
sterdam providing AIDS care. 
Inclusion criteria for the QOL study were: (1) a 
diagnosis of a symptomatic HIV infection or AIDS, 
(2) age 18 years and older and (3) ability to speak 
and read Dutch or English. An additional requirement 
for the non-trial patients was that they had to have 
been diagnosed within the previous six months. The 
trial patients also had to meet the specific inclusion 
criteria of the trial (e.g., CD4 count >150 cells/mm3, 
Kamofsky Performance Status (KPS)9 score >60).’ 
All patients were asked by their physician or a 
nurse to participate in the QOL study. Of the 49 trial 
patients approached, 45 (92%) agreed to participate. 
Among the four non-respondents, three patients 
preferred not to talk about their disease and one 
patient was already participating in another psycho- 
social study The exact number of eligible non-trial 
patients could not be determined due to privacy 
regulations of the participating hospitals. 
Design 
The first interviews with the non-trial patients were 
conducted within six months after their diagnosis of 
AIDS. The trial patients were interviewed after 
randomization, but prior to the start of the treatment. 
The follow-up assessments for both groups took place 
6 and 12 months after the first interview. Most 
patients were interviewed in their homes. In case of 
hospitalization, the questionnaires were administered 
on the hospital ward. 
Study instruments 
Demographic and clinical data 
A brief questionnaire was administered at the first 
interview to obtain information on age, living situ- 
ation, level of education and risk group. From the 
medical records, data were abstracted on the date of 
diagnosis of symptomatic HIV infection or AIDS, 
CDC classification, CD4 counts at the three assess- 
ment points and date of death. At the time of this 
study, CD4 counts were not performed routinely on 
non-trial patients, resulting in missing data for 22 of 
these patients. For the trial patients, the clinical data 
also included the KPS score9 as rated by the trial 
physician. 
The HOPES 
In the current study, we employed the revised version 
of the HOPES described by Ganz and associates in 
a recent paper.’ This version consists of 142 problem 
statements. There are 33 subscales that can be aggre- 
gated into five higher order summary scales and a 
miscellaneous scale: (1) Physical--eight subscales 
pertaining to physical problems and problems in 
daily functioning; (2) Psychosocial-including nine 
subscales relating to emotional functioning and prob- 
lems in communicating and interacting with relatives 
and friends; (3) Medical Interaction-three subscales 
pertaining to problems with interaction and 
communication with doctors and nurses; (4) Sexuality 
-containing two subscales relating to sexual interest, 
activities and functioning; and (5) Partner-five 
subscales relating to problems in communication and 
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interaction with a partner(s). The remaining six 
subscales were grouped under a miscellaneous scale. 
Patients were asked to rate the extent to which a 
problem statement applied to him/her during the 
past month on a 5-point scale ranging from 0 ‘not at 
all’ to 4 ‘very much’. Eighty-nine items were relevant 
to all patients. The remaining sections of the 
questionnaire, each of which is preceded by a screen- 
ing question, were rated only by patients to whom 
they applied. For example, patients in a steady 
relationship were asked questions pertaining to their 
relationship with their partner, whereas patients 
without such a relationship were asked questions 
relating to dating and initiating new relationships. 
The HOPES can be scored on three levels: a global 
score (calculated by dividing the sum of all the 14 
rated items by the total number of potential 
problems); the summary scales (the sum of the l-4 
rated items belonging to the summary scale divided 
by the number of potential problems in that scale); 
and the 33 more specific subscales. For all scales and 
the global score, higher scores indicate more problems. 
The current paper is restricted to the results 
pertaining to the five summary scale scores (Physical, 
Psychosocial, Medical Interaction, Sexual and 
Partner) and the global score. The content of the 
subscales of the Miscellaneous scale is extremely 
diverse, and should therefore only be scored and 
interpreted on a subscale level. 
The HOPES was translated into Dutch following 
a standard forward-backward procedure. The content 
of the translated version was reviewed by a range of 
internists and AIDS consultants who provide medical 
and psychosocial care to HIV-infected individuals. 
Additionally, the questionnaire was pretested on a 
number of patients. Doctors, nurses and patients 
reported that the problem statements reflected the 
experiences of patients with the disease and its treat- 
ment, thus lending support to the face and content 
validity of the questionnaire. 
The EORTC QLCbC30 
Quality of life was also assessed with the EORTC 
QLQC30, a 30-item self-report questionnaire origi- 
nally developed for use with cancer patients.” The 
QLQCSO includes five functioning scales (physical, 
role, emotional, cognitive and social functioning), 
three symptom scales (pain, fatigue and nausea and 
vomiting), and an overall quality of life scale. The 
remaining six single items refer to additional physical 
symptoms (e.g., shortness of breath, diarrhea), and 
to financial difficulties patients may experience as a 
result of their disease or treatment. The time-frame 
of the questions encompasses the past week, and the 
majority of the items can be answered on a Cpoint 
Likert scale. Scores of all of the QLQC30 scales and 
individual items were transformed linearly to a O-100 
point scale. High values on the functioning and over- 
all QOL scales indicate high levels of functioning and 
QOL. Conversely, higher scores on the symptom 
scales indicate higher levels of symptomatology. 
In a study of 156 patients with a symptomatic HIV 
infection or AIDS (including the 106 patients of the 
present study), the QLQC30 exhibited acceptable 
levels of reliability and validity.” In the current analysis, 
the QLQCSO is used as a concurrent measure to 
examine the construct validity of the HOPES. 
Statistical analysis 
Scale strucfure. The multitrait analysis program 
(MAP-R)‘* was used to evaluate the hypothesized 
scale structure of the HOPES. Item-scale correlation 
matrices were employed to evaluate the convergent 
and discriminant validity of the items of the five 
summary scales of the HOPES. Evidence of item 
convergent validity is provided when an item corre- 
lates substantially (Lo.40) with its own scale, 
corrected for overlap. Item divergent validity is 
evidenced when an item correlates significantly (52 
standard errors) higher with its own hypothesized 
scale than with other scales.” Given that the standard 
error (SE = l/dN) used as the criterion for judging 
scaling successes and errors is highly sensitive to 
sample size and that, in the current case, the sample 
size was relatively small (n = 106 for the Physical, 
Psychosocial and Medical Interaction scales; n = 55 
and n = 54 for the Sexual and Partner scales, respec- 
tively) a scaling success was counted when an item 
correlated higher (21 SE) with its own scale than with 
another scale. A scaling error was counted when an 
item correlated lower with its own scale than with 
another scale. 
Due to the presence of sections within the HOPES 
that apply only to specific subgroups of patients, 
some summary scales were not completed by all 
patients. Since the MAP-R program does not accom- 
modate missing data, three multitrait analyses were 
performed; one for the items of the three summary 
scales Physical, Medical Interaction and Psychosocial; 
one for the items of the Sexual scale; and one for the 
items of the Partner scale. 
Reliability. The internal consistency reliability of the 
five summary scales was estimated by Cronbach’s 
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alpha coefficient. Reliability was considered accept- 
able when Cronbach’s 01 were >0.70.13 
Validity. Four sets of analyses were carried out to 
evaluate the construct validity of the HOPES. First, 
we examined the correlations among the five summary 
scales, and between the summary scores and the 
global score. Moderate correlations (in the range 0.30- 
0.50) were expected among the summary scales. More 
substantial correlations (>0.50) were expected between 
the five summary scales and the global score, as they 
were all considered aspects of global QOL. 
Second, the correlations between the HOPES 
summary and global scores, and the QLQC30 
subscales were examined. High correlations (>0.60) 
were expected among scales pertaining to the same 
construct (e.g., between the physical scale of the HOPES 
and the subscales physical and role functioning of 
the QLQ-C30). Weaker associations were expected 
between subscales of the HOPES and the QLQC30 
that were conceptually distinct (e.g., sexuality and 
cognitive functioning). Correlations were calculated 
by means of Pearson product-moment correlations. 
The third set of analyses evaluated the extent to 
which the summary scales of the HOPES could 
discriminate between subgroups of patients known 
to differ in clinical status. At all three assessment 
points, scores of patients with AIDS vs. those with a 
symptomatic HIV-infection [previously termed AIDS 
Related Complex (ARC)] were compared. Previous 
studies have indicated that patients with AIDS report 
more problems in physical and role functioning, but 
less psychological problems than patients with 
ARC. 14’5,‘6,17Thus, it was hypothesized that patients 
with AIDS would report poorer physical functioning, 
but better psychosocial functioning. Student’s t-tests 
were used to compare the mean scale scores for the 
subgroups at baseline and follow-up. 
Fourth, changes over time in scale scores for the 
82 surviving patients were examined by means of 
repeated measures ANOVA. In a longitudinal study 
design with symptomatic and AIDS patients, Lubeck 
and colleagues’5*‘6found an increase in disease symp- 
toms, and significant declines in all aspects of role 
functioning, but no significant declines in cognitive 
functioning or mental health. Accordingly, we 
predicted that, over time, patients would generally 
report an increase in physical problems, but a 
decrease in psychosocial problems. 
Finally, a valid measure of QOL should be respon- 
sive to clinically important changes in health status 
over time. The observed changes in patients’ CD4 
lymphocytes are commonly used as a prognostic 
marker of clinical progression. When subjects’ CD4 
counts decrease, their risk of clinical progression 
increases.‘* To evaluate the responsiveness of the 
HOPES to changes in CD4 counts, the changes over 
time in mean HOPES scores of stable or improved 
patients were compared with those of deteriorated 
patients by means of repeated measures ANOVA. 
Deteriorated patients were defined as those whose 
CD4 count had decreased significantly (>lO%) over 
a one year period. Stable/improved patients were 
characterized by stable &lo%) or increased (>lO%) 
CD4 counts at 12 months follow-up. We hypothesized 
that stable/improved patients would have approxi- 
mately the same or better HOPES scores at 12 months 
follow-up as at baseline, whereas patients with 
decreased CD4 counts were expected to score worse 
on the HOPES, particularly the Physical scale. 
All data analyses were performed using SPSS 4.0. 
For t-tests and repeated measures ANOVA, t- and 
F-values associated with chance probabilities of less 
than 0.05 were considered statistically significant. 
Results 
Description of the sample at baseline and follow-up 
One hundred and six patients were enrolled in the 
study and evaluated at baseline. At 6 and 12 months 
follow-up, 93 and 82 patients completed the 
questionnaires, respectively. During the one year 
follow-up, 18 patients had died, four patients 
declined further participation, and data for two 
patients were missing at either the 6 or 12 month 
assessments due to severe illness. 
As is shown in Table 1, the sample consisted 
primarily of well-educated, male homo-/bisexuals 
with AIDS. On average, patients had been diagnosed 
with AIDS or symptomatic HIV infection within the 
past four months. The mean KPS score (available for 
the trial patients only) was high, indicating nearly 
normal physical functioning. Approximately half of 
the sample had CD4 counts below 200 celIs/mm3. At 
12 months follow-up, the mean KPS score was still 
high (Mean = 90.5; SD = 12.6; n = 39). The mean CD4 
count had decreased to 176 cells/mm3 (SD = 178; n = 61) 
with 70% of the patients having CD4 counts below 
200 cells/mm3. 
Feasibility 
On average, patients needed approximately a half 
hour (n = 103, range 9-70 minutes) to complete the 
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Table 1. Baseline characteristics of patients, n = 106 
Characteristic n % 
Sex 
Male 
Female 
Mean (SD) age in years 
Range 
Risk group 
Bi-/homosexual 
Heterosexual 
Heterosexual/ex-IVDU* 
Education+ 
Low 
Middle 
High 
Living arrangement 
Alone 
With partner 
Other (family, friends, 
nursing home) 
Diagnosis5 
AIDS 
Symptomatic HIV infection 
(ARC) 
99 
7 
36.0 
22-65 
96 
5 
3 
32 30.5% 
34 32.4% 
39 37.1% 
53 50.0% 
36 35.8% 
15 14.2% 
69 
23 
AIDS/Kaposi Sarcoma 14 
Mean time (SD) since diagnosis 127 days 
Range l-631 days 
CD4+ count (n = 69) 
Mean (SD) 212 
Range 1 O-950 
KPS score (n = 48) 
Mean (SD) 92.7 
Range 80-100 
93.4% 
6.6% 
(7.8) 
92.5% 
4.7% 
2.8% 
65.1% 
21.7% 
13.2% 
(114) 
(162) 
(7.8) 
KPS=Kamofsky performance status; 
IVDU=intravenous drug user 
l Revised version of the 1987 Centers for Disease 
Control surveillance case definition of AIDS. 
+ Low education corresponds to O-11 yrs, middle to 
12-15 yrs, and high to 216 yrs of education. 
HOPES at baseline, and 22 minutes at month 6 and 
12 (Month 6: n = 91, range 10-45 min; Month 12: n = 
80, range 12-45 min) . The wide range of time required 
to complete the HOPES was due to the fact that some 
patients took the opportunity, while filling out the 
questionnaire, to talk about their illness with the 
research assistant. 
The reliability coefficients of the five summary 
scales were all high, with a mean 01 coefficient of 0.87 
at baseline, and 0.88 at 6 and 12 months (see Table 2). 
Validity 
At baseline, and at 6 and 12 months follow-up, Correlations among the summary scales. The inter- 
three, three and five patients, respectively, were scale correlations at baseline and follow-up were 
unable to complete the questionnaire on their own examined (data not shown). In accordance with II 
because of difficulty writing (due to polymyelopathy), priori expectations the correlations among the scales 
or because they were too ill. On these occasions, the were of a moderate magnitude, with the exception 
questionnaire was administered in the form of an 
interview. 
The system of the screening questions incorporated 
in the HOPES was generally clear to patients, and 
they reported few problems in understanding the 
questions. However, some double-negative question- 
response combinations caused problems (e.g. item: ‘I 
have pain not controlled by medication’; response: ‘not 
at all’). Further, some items were not relevant to all 
of the patients (e.g. ‘Do you have difficulty driving 
a car’, for patients who either did not have a driver’s 
license or had not driven a car during the past month). 
Descriptive statistics 
The majority of the patients scored toward the healthy 
end of the five summary scales and the global scale 
(Table 2). The highest baseline score (most problems) 
was obtained on the sexuality scale. At follow-up, 
the highest scores were observed on the Physical and 
Sexual scales. 
Scale structure and reliability 
The results of the three multi-trait scaling analyses 
of the baseline HOPES indicated that 29 of the 106 
items (27%) did not meet the standard criterion for 
item convergent validity (item-scale correlation 
~0.40); 13 of these items belonged to the Physical 
scale; six to the Psychosocial scale; seven to the Partner 
scale; and three to the Sexual scale. In total, there 
were 240 tests of item discriminant validity. Scaling 
successes were noted in 82.3% of the tests of item- 
discriminant validity at baseline. Thirty-four scaling 
errors (17.7%) were noted, five for items of the Physi- 
cal scale, eight for items of the Psychosocial scale, 17 
for items of the Partner scale, and four for items of 
the Sexual scale. 
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Table 2. The HOPES: descriptive statistics and reliability for the summary scales and global score at baseline 
and follow-up 
No. of 
Summary scales* 
Physical 
Psychosocial 
Medical interaction 
Sexual5 
Partners5 
Global* 
Items 
30 
37t 
11 
10 
18 
Baseline: (n = 106) 6 months: (n = 93) 12 months: (n = 62) 
Mean (SD) 
0.:9 
Mean (SD) 
0.;2 
Mean (SD) 
0.69 (0.47) 0.74 (0.58) 0.92 (0.61) 0.:2 
0.76 (0.52) 0.93 0.88 (0.47) 0.92 0.70 (0.45) 0.92 
0.36 (0.55) 0.89 0.28 (0.39) 0.84 0.25 (0.40) 0.86 
1.13 (0.80) 0.80 1.21 (0.81) 0.83 1.25 (0.85) 0.84 
0.39 (0.42) 0.88 0.39 (0.47) 0.90 0.42 (0.47) 0.88 
0.67 (0.41) 0.65 (0.39) 0.71 (0.38) 
SD = standard deviation; a = Cronbach’s alpha coefficient 
l Higher values indicate more problems 
t The subscales ‘children’ and ‘at work concerns’ (8 items) are excluded because these questions only 
applied to a small number of patients. 
$ Dependent on app 
5 
licability of the screening questions 
Sample size at baseline: n = 54; 6 months: n = 88; 12 months: n = 77 
55 Sample size at baseline: n = 54; 8 months: n = 50; 12 months: n = 45 
Table 3. Mean HOPES scores at baseline and 12 months follow-up for patients with AIDS vs. patients with a 
symptomatic HIV infection (ARC) 
Baseline 12 month follow-up 
ARC (n= 23) AIDS (n= 63) ARC (n = 22) AIDS (n = 60) 
Summary scale* Mean (SD) Mean (SD) p Mean (SD) Mean (SD) p 
Physical 0.88 (0.44) 0.70 (0.48) 0.77 0.84 (0.44) 1.02 (0.64) 0.01 
Psychosocial 1 .Ol (0.59) 0.70 (0.49) 0.01 0.95 (0.58) 0.61 (0.38) 0.02 
Medical interaction 0.40 (0.81) 0.35 (0.53) 0.65 0.27 (0.40) 0.24 (0.40) 0.78 
Sexual 1.26’ (0.82) l.Ogb (0.79) 0.42 1.18’ (0.86) 1 .28d (0.86) 0.67 
Partner 0.41 e (0.35) 0.38’ (0.44) 0.82 0.548 (0.53) 0.37” (0.45) 0.30 
Global 0.78 (0.45) 0.63 (0.40) 0.13 0.73 (0.43) 0.70 (0.38) 0.70 
l Higher values indicate more problems 
a n=20; bn=76; ’ n=20; d n=57;’ n=ll; f n=47;g n=12 ; h n=33 
of the sexual and medical interaction scales that were 
correlated in the range of 0.08-0.23. All summary 
scales correlated substantially with the global score 
(range 0.47-0.92). Consistently, the strongest correlate 
of the global score was the Psychosocial scale (0.79- 
0.92), followed by the Physical scale (0.75-0.79). Over 
time, the magnitude of the correlations declined. The 
mean inter-scale correlations declined from 0.48 at 
baseline to 0.39 and 0.28 at 6 and 12 months follow-up, 
respectively. 
Correlations among the HOPES and QLQGO. Consistent 
with expectations, the correlations between the 
summary scales of the HOPES and the QLQ-C30 
subscales indicated that the conceptually related scales 
were highly intercorrelated (data not presented in 
tabular form). For example, the correlation between 
the subscales assessing physical functioning ranged 
from 0.49-0.77; those among the scales assessing 
psychosocial functioning ranged from 0.41X1.68. The 
subscales pertaining to conceptually distinct domains 
(e.g., sexuality and cognitive functioning) exhibited 
weak correlations (cO.10). 
Comparison of AIDS and ARC patients. The mean 
scores at baseline and 12 months follow-up of patients 
with AIDS vs. ARC are shown in Table 3. As expected, 
patients with AIDS reported significantly fewer 
psychosocial problems at baseline and 12 months 
follow-up than patients with ARC. At 6 months 
follow-up, no significant differences could be detected 
between the two groups. Contrary to our expecta- 
tions, the patients with AIDS reported significantly 
more physical problems at 12 months follow-up only 
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Changes over time. For the 82 surviving patients, main 
effects for time were found for the Physical and Psycho- 
social scales (see Table 4). As expected, patients reported 
significantly more physical problems at month 12 than 
at baseline and month 6. Psychosocial functioning 
had improved significantly at month 6, and remained 
stable thereafter. Additionally a trend toward report- 
ing fewer problems in medical interactions was found 
(p = 0.06). No significant change was observed for 
the global score, which may be explained by the fact 
that the deterioration in physical functioning had 
cancelled out the improvement in psychosocial 
functioning. 
l-he HOPES 
Responsiveness to clinical changes. Prior to performing 
the repeated measures ANOVA, statistical tests were 
performed to confirm whether the increase or 
decrease in CD4 counts at follow-up was statistically 
significant. The 19 stable/improved patients evidenced 
significantly higher CD4 counts at 12 months follow- 
up [Baseline: Mean = 269 (SD = 176); 12 months: 
Mean = 339 (SD = 198); p < O.OOl]. The CD4 count of 
the 46 deteriorated patients had declined significantly 
[Baseline: Mean = 230 (SD = 170); 12 months: Mean = 
98 (SD = 104); p <O.OOl]. 
The repeated measures ANOVA revealed signifi- 
cant differences over time between the patients with 
Table 4. The HOPES summary and global scores: changes over time for 82 survivors 
Baseline 6 months 
Summary scales’ Mean (SD) Mean (SD) 
Physical 0.68 (0.48) 0.69 (0.54) 
Psychosocial 0.83 (0.55) 0.70 (0-W 
Medical interaction 0.37 (0.56) 0.29 (0.41) 
Sexual (n = 72) 1.08 (0.72) 1.14 (0.81) 
Partner (n = 35) 0.34 (0.35) 0.31 (0.41) 
Global 0.70 (0.44) 0.64 (0.40) 
l Higher values indicate more problems 
+ F-value and pvalue reported for main effect for time 
12 months 
Mean (SD) F+ P 
0.92 (0.61) il.99 0.00 
0.70 (0.45) 5.80 0.00 
0.25 (0.40) 2.86 0.06 
1.24 (0.81) 1.95 0.15 
0.37 (0.46) 0.62 0.54 
0.71 (0.38) 2.14 0.12 
Table 5. Changes over time in HOPES scores for patients with stable/improved CD4 counts vs. deteriorated 
CD4 counts 
Summary scsles* 
Physical 
Psychosocial 
Medical interaction 
Sexual (n = 72) 
Partner (n = 35) 
Global 
lnstt 
Baseline 
Mean (SW 
6 months 
Mean (SW 
12 months 
Mean (SW F+ P 
0.71 (0.57) 0.59 (0.46) 0.63 (0.50) 4.62 0.01 
46$ 0.68 (0.44) 0.71 (0.57) 1 .Ol (0.65) 
19 1 .Ol (0.58) 0.81 (0.52) 0.80 (0.50) 0.90 0.41 
46 0.78 (0.52) 0.69 (0.50) 0.71 (0.45) 
19 0.54 (0.76) 0.35 (0.52) 0.23 (0.35) 2.66 0.07 
46 0.31 (0.48) 0.26 (0.36) 0.30 (0.47) 
18 1.18 (0.72) 1.05 (0.89) 0.95 (0.78) 3.74 0.03 
41 1.11 (0.71) 1.16 (0.77) 1.38 (0.81) 
7 0.29 (0.19) 0.25 (0.31) 0.24 (0.38) 0.75 0.48 
27 0.34 (0.38) 0.24 (0.23) 0.36 (0.47) 
19 0.83 (0.52) 0.66 (0.43) 0.64 (0.37) 5.22 0.01 
46 0.67 (0.40) 0.63 (0.41) 0.76 (0.40) 
l Higher values indicate more problems 
+ F-value and pvalue reported for interaction effect (group x time) 
it n= 19: stable/improved CD4 counts 
n= 46: diminished CD4 counts 
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sustained or improved CD4 counts vs. those with 
decreased CD4 counts for the Physical and Sexual 
scales, and the global scores (Table 5). Whereas the 
scores of the stable/improved patients improved or 
remained at approximately the same level, patients 
with decreased CD4 counts reported a deterioration 
of their physical and sexual functioning, and global 
QOL over time. No significant differences between 
the two groups over time were found with respect 
to psychosocial functioning, problems in their partner 
relationship or in their interaction with the medical 
team. 
Discussion 
The primary aim of this study was to examine the 
feasibility and psychometric properties of the HOPES 
in longitudinal research with HIV-infected and AIDS 
patients. In a group of predominantly male, bi-/homo- 
sexuals with a symptomatic HIV infection or AIDS, 
the HOPES proved to be a feasible instrument for 
assessing health-related quality of life. Patients 
reported few problems in understanding the 
questions and seldom made mistakes with the screen- 
ing questions. However, the level of education of our 
patients was very high and the HOPES was admin- 
istered under optimal conditions whereby an 
interviewer was always present to clarify misunder- 
standings and to guide the respondents through the 
branching system of the questionnaire. 
The HOPES proved to be a highly reliable instrument, 
with the internal consistency coefficients for the five 
summary scales being 20.80 at all assessments. The 
multitrait scaling analysis provided moderate 
support for the hypothesized scale structure of the 
HOPES. Twenty-seven and 18 per cent of the items 
did not meet the criteria for item-convergent and 
item-divergent validity, respectively. In part, this could 
be explained by the effect of the relatively small sample 
size, particularly for the Sexual and Partner scale. 
The results generally were supportive of the 
construct validity of the HOPES. The majority of the 
inter-scale correlations were moderate and in the 
predicted direction. In addition, the correlations 
between the summary scales of the HOPES and rele- 
vant subscales of the QLQC30 were all substantial 
and in the predicted direction. The HOPES was 
responsive to changes in CD4 counts over time. A 
deterioration in immune function was reflected in 
poorer scores on the HOPES, whereas a stable or 
improved immune function was accompanied by 
equal or even better scores on the HOPES. 
The HOPES discriminated between subsamples of 
AIDS and ARC patients, in accordance with a priori 
hypotheses, particularly for the Psychosocial scale. 
Contrary to our expectations, patients with AIDS only 
reported significantly poorer physical functioning at 
12 months follow-up. This might indicate that 
patients with AIDS experience a more rapid deterio- 
ration in physical functioning than patients with ARC. 
Further, the HOPES was able to detect significant 
changes over time in accordance with hypotheses 
derived from previous studies. Over time, the sur- 
viving patients reported more physical problems and 
fewer psychosocial problems. When the changes in 
CD4 counts were also taken into account, deteriora- 
tion in physical functioning was found to be more 
prominent among patients with decreased CD4 
counts. Improvement in psychosocial functioning did 
not appear to be related to changes in CD4 counts. 
In addition, among the surviving patients, no signifi- 
cant deterioration in sexual functioning was found. 
Upon closer inspection, however, it appeared that 
patients with decreased CD4 counts reported more 
sexual problems over time while patients with stable 
or improved CD4 counts reported fewer sexual prob- 
lems. 
The HOPES provides both a global score and sum- 
mary scores for specific QOL dimensions. However, 
prudence is called for in interpreting the global score. 
We found no change in the global score over time 
while we did observe simultaneous improvement and 
deterioration on the summary scales. Moreover, the 
absolute value of the HOPES global score is dependent 
on the number of sections that apply to a given 
patient. Patients for whom all sections apply may 
obtain a higher global score than those for whom 
only a subset of sections apply This scoring artifact 
could lead one to erroneously conclude that the 
former patients have a poorer overall QOL. 
In conclusion, the results of the study support the 
feasibility, reliability and validity of the HOPES in 
assessing the quality of life of patients with AIDS or 
a symptomatic HIV-infection. The strength of the 
HOPES is that it allows for a detailed assessment of 
the daily problems of HIV-infected patients, including 
topics such as sexuality and the interaction with 
health care providers that are usually not covered by 
other QOL instruments. However, the price for this 
detailed assessment is the 20-30 minutes needed for 
completion. For use in clinical trials, where time for 
QOL assessments is usually limited, a short-form (SF) 
version analogue to the CARES-SF’9 may be required. 
In future studies, the feasibility of the HOPES in 
populations with lower educational levels and under 
less optimal administration conditions needs to be 
addressed. In addition, the scale structure of the 
346 Quality of Life Research Vol5 1996 
HOPES requires closer scrutiny in larger samples. To 
further examine the construct validity of the HOPES, 
studies in healthier, asymptomatic as well as in late 
stage disease populations are needed. 
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